Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
St. Jude Children's Research Hospital
Mayo Clinic
GlaxoSmithKline
UNC Lineberger Comprehensive Cancer Center
University of Wisconsin, Madison
Barbara Ann Karmanos Cancer Institute
Cedars-Sinai Medical Center
University of Virginia
Catalysis SL
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Northwestern University
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Celgene
City of Hope Medical Center
University of Texas Southwestern Medical Center
Albert Einstein College of Medicine
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
University of Louisville
Fred Hutchinson Cancer Center
Rutgers, The State University of New Jersey
Barbara Ann Karmanos Cancer Institute
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
National Cancer Institute (NCI)
Indiana University
University of Minnesota
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
INSYS Therapeutics Inc
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
University of Kentucky
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)